Related references
Note: Only part of the references are listed.Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent
Anke E. M. van Erp et al.
ONCOTARGET (2017)
PD-L1 Expression Is Associated with FOXP3+Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis
Yi Que et al.
JOURNAL OF CANCER (2017)
T-Cell Infiltration and Clonality Correlate With Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Expression in Patients With Soft Tissue Sarcomas
Seth M. Pollack et al.
CANCER (2017)
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
Chan Kim et al.
BMC CANCER (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas
Semra Paydas et al.
MEDICAL ONCOLOGY (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P. D'Angelo et al.
HUMAN PATHOLOGY (2015)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
Jung Ryul Kim et al.
PLOS ONE (2013)
The Epidemiology of Sarcoma
Zachary Burningham et al.
CLINICAL SARCOMA RESEARCH (2012)
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
R. Houston Thompson et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
